Login

Seagen Inc. 8-K SEC Filings

Filed On Filing
14 Dec 2023 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more

SECTION 1. REGISTERED OFFICE. The address, including street, number, city, and county, of the registered office of Seagen Inc. (the “Corporation”) in the State of Delaware is the Corporation Trust Center, 1209 Orange Street, City of Wilm...

12 Dec 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc. (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc. (“Pfizer”) and Aris Merger Sub, Inc., a wholly owned sub...

01 Nov 2023 8-K: Results of Operations and Financial Condition

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

19 Oct 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc., a Delaware corporation (“Pfizer...

22 Sep 2023 8-K: Other Events

BOTHELL, Wash. and TOKYO – September 22, 2023 — Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfor...

05 Sep 2023 8-K: Other Events

BOTHELL, Wash., and COPENHAGEN, Denmark, September 4, 2023 — Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with dis...

16 Aug 2023 8-K: Other Events

Seagen Phase 3 Trial of TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

02 Aug 2023 8-K: Results of Operations and Financial Condition

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

14 Jul 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc., a Delaware corporation (“Pfizer...

14 Jun 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc., a Delaware corporation (“Pfizer...

01 Jun 2023 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Shareholders of Seagen Inc. (the “Company”) held on May 31, 2023, the Company’s shareholders voted on the five proposals listed below. The final results of the votes regarding each proposal are set forth below. T...

31 May 2023 8-K: Submission of Matters to a Vote of Security Holders; Other Events

BOTHELL, Wash.—(BUSINESS WIRE)—Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which P...

23 May 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc., a Delaware corporation (“Pfizer...

15 May 2023 8-K: Other Events

As previously disclosed, on March 12, 2023, Seagen Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Pfizer Inc., a Delaware corporation (“Pfizer...

27 Apr 2023 8-K: Results of Operations and Financial Condition

-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million-

03 Apr 2023 8-K: Other Events

On April 3, 2023, Seagen Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has granted PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) accelerated approval in the United States as a combi...

13 Mar 2023 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 12, 2023, is by and among Pfizer Inc., a Delaware corporation (“Parent”), Aris Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Mer...

15 Feb 2023 8-K: Results of Operations and Financial Condition

-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion-

19 Jan 2023 8-K: Other Events

On January 19, 2023, Seagen Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectab...

18 Nov 2022 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Meetings of stockholders shall be held at any place, within or outside the State of Delaware, or may not be held at any place, but may instead be held solely by means of remote communication, as may be designated by resolution of the Boa...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support